This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ESMO Preview: Cancer Stocks to Watch

BOSTON ( TheStreet) -- A key European cancer drug research meeting -- the 35th European Society for Medical Oncology (ESMO) Congress -- kicks off Friday in Milan and will include key data presentations from the following companies:

Dendreon (DNDN)
Drug: Provenge
Indication: Prostate cancer
Presentation date: Sat. Oct. 9

The Provenge data from four double-blind, placebo-controlled studies is not new, but this is the first time Dendreon will present Provenge efficacy and safety data to a European medical audience. Provenge is not approved in Europe. Dendreon is expected to make its European regulatory plans public later this year or early next year.

Amgen (AMGN - Get Report)
Drug: AMG386
Indication: Ovarian cancer
Presentation: Sat. Oct. 9

Follow-on data to be presented from a phase II study of AMG386 plus paclitaxel in patients with advanced ovarian cancer. At the ASCO meeting in June, a 10 mg dose of AMG386 plus paclitaxel demonstrated a 7.2-month median progression-free survival compared to a median 4.6-month PFS for placebo plus paclitaxel.

Roche and ImmunoGen (IMGN - Get Report)
Drug: TDM-1
Indication: Breast cancer
Presentation: Sun. Oct. 10

Interim results will be presented from an open-label phase II study of TDM-1 compared against Herceptin plus taxotere in front-line metastatic breast cancer. These data are important because it will provide the first (early) clue about TDM-1's ability to eventually replace Herceptin as the front-line drug treatment of choice for women newly diagnosed with metastatic Her-2 positive breast cancer.

Johnson & Johnson (JNJ - Get Report)
Drug: Abiraterone
Indication: Prostate cancer
Presentation date: Monday, Oct. 11

J&J announced in September that treatment with abiraterone helps men with advanced, metastatic prostate cancer live longer, but the details -- how big is that survival benefit? -- was not disclosed. Researchers at ESMO will present the full data from the abiraterone phase III study, which enrolled metastatic prostate cancer patients previously treated with chemotherapy.

Seattle Genetics (SGEN - Get Report)
Drug: SGN75
Indication: Non-Hodgkin lymphoma and kidney cancer
Presentation: Mon. Oct. 11

Early, phase I data on SGN-75, another "armed antibody" drug candidates in Seattle Genetics' cancer drug pipeline. These data are from a dose escalation study enrolling patients with relapses refractory NHL or metastatic kidney cancer.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $141.47 -2.50%
DNDN $0.06 -6.02%
IMGN $7.16 -6.30%
JNJ $102.38 1.80%
OXGN $0.59 -3.00%


Chart of I:DJI
DOW 15,877.65 -327.32 -2.02%
S&P 500 1,835.99 -44.06 -2.34%
NASDAQ 4,238.93 -124.2140 -2.85%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs